When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
http://academic.oup.com/jnci/article-pdf/99/6/428/7689088/djk091.pdf
Reference5 articles.
1. End Points and United States Food and Drug Administration Approval of Oncology Drugs
2. New Guidelines to Evaluate the Response to Treatment in Solid Tumors
3. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
4. Methods for interval-censored data
5. Maximum Likelihood Estimation for Interval-Censored Data Using a Weibull- Based Accelerated Failure Time Model
Cited by 150 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Statistical approaches for component-wise censored composite endpoints;Clinical Trials;2024-08-08
2. Measurement error and bias in real-world oncology endpoints when constructing external control arms;Frontiers in Drug Safety and Regulation;2024-07-19
3. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial;The Lancet Oncology;2024-07
4. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials;European Journal of Cancer;2024-05
5. Estimated small dense low‐density lipoprotein cholesterol and nonalcoholic fatty liver disease in nonobese populations;Journal of Diabetes Investigation;2023-12-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3